Pathophysiology of inflammation and tissue injury in multiple sclerosis: What are the targets for therapy

Journal of the Neurological Sciences

Volumn 306, Issue 1-2, 2011, Pages 167-169

  Lassmann, Hans ^a  

^a Medical University of Vienna   (Austria)

Author keywords

Multiple sclerosis; Pathophysiology; Therapy

Indexed keywords

4 AMINOPYRIDINE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BETA INTERFERON; CD4 ANTIBODY; GLATIRAMER; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23 ANTIBODY; NATALIZUMAB; RITUXIMAB; SCAVENGER; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM TUMOR; CONFERENCE PAPER; DISEASE COURSE; DRUG TARGETING; DRUG TREATMENT FAILURE; EXPERIMENTAL MODEL; HUMAN; LEUKEMIA; LYMPHOMA; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADICAL REACTION; SOFT TISSUE INFLAMMATION; TISSUE INJURY; TREATMENT PLANNING;

ANTI-INFLAMMATORY AGENTS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS;

EID: 79958771184     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2010.07.023     Document Type: Conference Paper

References (36)

1. Lassmann H, Brück W, Lucchinetti C. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210-8. (Pubitemid 46466140)
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11. (Pubitemid 26134623)
3. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 2004;101(Suppl 2):14599-606. (Pubitemid 39346730)
4. Wiendl H, Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 2009;72:1008-15.
5. Giacomini PS, Darlington PJ, Bar-Or A. Emerging multiple sclerosis disease-modifying therapies. Curr Opin Neurol 2009;22:226-32.
6. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Ustekinumab MS Investigators. Repeated subcutaneous injections of Il12/23 p40 neutralizing antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7:796-804.
7. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88. (Pubitemid 351240747)
8. Lassmann H. Comparative Neuropatholohy of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis. Springer Vlg, Berlin: Heidelberg; 1983. p. 1-135.
9. Taoufik E, Tseveleki V, Euagelidou M, Emmanouil M, Voulgari-Kokota A, Haralambous S, et al. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis. Neurodegener Dis 2008;5:32-7. (Pubitemid 350261814)
10. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansion of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000;192:393-404. (Pubitemid 30629164)
11. Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, Rajewsky K, et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA 2004;101:2428-33. (Pubitemid 38269328)
12. Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 2005;128:1747-63.
13. Bar-Or A, Calabresi PA, Arnols D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open label, phase I trial. Ann Neurol 2008;63:395-400. (Pubitemid 351499869)
14. Frischer JM, Bramow S, Dal Bianco A, Lucchinetti C, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis. Brain 2009;132:1175-89.
15. Anderton SM, Fillatreau S. Activated B cells in autoimmune disease: the case for a regulatory role. Nat Clin Pract Rheumatol 2008;4:657-66.
16. Ascherio A, Munger KL. Epstein Barr virus infection and multiple sclerosis. J Neuroimmune Pharmacol 2010 epub ahead of press.
17. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247-69.
18. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, Gordon G, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 2006;65:855-65. (Pubitemid 44371231)
19. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-74. (Pubitemid 38656388)
20. Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S. Central nervous system prophylaxis in adults with acute lymphobrastic leukemia. Cancer 2010;116: 2290-300.
21. Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics 2009;6:587-97.
22. Villela L, Garcia M, Caballero R, Borbolla-Escoboza JR, Bolanos-Meade J. Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma. Anticancer Drugs 2008;19:917-20.
23. Sifrin V, Vogt J, Radbruch H, Nitsch R, Zipp F. Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci 2010;33:202-10.
24. Trapp B, Stys P. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009;8:280-91.
25. Mahad D, Ziabreva I, Lassmann H, Turnbull D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 2008;131:1722-35. (Pubitemid 351957459)
26. Veto S, Acs P, Bauer J, Lassmann H, Berente Z, Setalo G, et al. Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death. Brain 2010;133:822-34.
27. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005;133:3-13. (Pubitemid 40804810)
28. Mahad D, Ziabreva I, Campbell G, Lax N, Hanson PS, Lassmann H, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009;132: 1161-74.
29. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006;59:478-89. (Pubitemid 43358068)
30. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, et al, on behalf of the Fampridine MS-F203 investigation. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373:732-8.
31. Lisak RP, Benjamins JA, Bealmear B, Nedelkoska L, Studzinski D, Redland E, et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation. J Neuroinflammation 2009;4:30.
32. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of oxygen and nitrogen species. Brain Pathol 1999;9:69-92. (Pubitemid 29056521)
33. Lu F, Selak M, O'Connor J, Croul S, Lorenzana C, Butunoi C, et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci 2000;177:95-103.
34. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett 2008;442:195-8.
35. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated activity of microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol 2008;18:86-95.
36. Hammond KE, Metcalf M, Carvajal L, Okuda DT, Srinivasan R, Vigneron D, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707-13.